Product Introduction
IdeS Protease, fully known as Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS), is a cysteine hydrolase enzyme produced and secreted extracellularly by the human pathogen Streptococcus pyogenes. This protease exhibits extremely high substrate specificity, recognizing only IgG and cleaving at a specific site in the hinge region of the antibody, resulting in the hydrolysis of IgG into intact F(ab’)2 fragments and Fc fragments. IdeS can recognize IgG from human and various other animal sources, such as human, rabbit, monkey, sheep, and human-animal chimeric IgG, etc. IdeS cannot recognize and cleave mouse IgG1/IgG2b, rat, pig, cow, and goat IgG. It has moderate enzymatic activity towards mouse IgG2a and IgG3, and for the cleavage of mouse IgG2a and IgG3, it is recommended to increase the amount of IdeS (the recommended dosage is 5-10 times the normal amount). IdeS cannot cleave monoclonal molecules that are not of the IgG subtype, including IgA, IgM, IgD, and IgE.
Figure 1. Schematic Diagram of IdeS Protease Cleavage
Yeasen currently offers IdeS enzyme (Cat#20412ES), which is recombinantly expressed in Escherichia coli, with high purity and good enzymatic activity.
Product Applications
1.Antibody Drug Preparation and CharacterizationIdeS enzyme is used as a tool enzyme in the preparation and structural characterization analysis of antibody drugs. It is a valuable tool for characterizing therapeutic antibodies, monoclonal antibodies, antibody-drug conjugates, Fc fusion proteins, and antibody-drug complexes.
2.Drug Development
IdeS enzyme can also assist in drug development in certain fields, as shown in the table below.
|
Gene Therapy |
Pre-treatment with IdeS during AAV vector infusion can eliminate AAV neutralizing antibodies, restoring the efficacy of re-administered AAV vectors. |
|
Kidney Transplantation |
Desensitization therapy after HLA-mismatched donor kidney transplantation |
|
Neuromyelitis Optica Spectrum Disorders |
Inactivate antibodies, inducing downstream reactions following the binding of pathogenic antibody-antigen complexes |
|
Other Diseases |
Pulmonary Hemorrhage-Nephritis Syndrome Thrombotic Thrombocytopenic Purpura |
Product Features
High Specificity: Single cleavage site: CPAPELLG/GPSVF.
Fast Reaction: 30-minute rapid cleavage, significantly faster than papaya proteinase and pepsin.
High Stability: Each batch of product undergoes strict quality control to ensure batch-to-batch stability.
Simple Reaction Conditions: Compatible with various pH buffer solutions, no need for reducing agents or auxiliary reagents.
Reference Literature Application Example [1]
Figure 2. Schematic diagram illustrating the synthesis of 99mTc-MAG3-Cet-F(ab′)2
Figure 3. (b) The HPLC result of MAG3-Cet-F(ab′)2 and MAG3-Cet-Fc after digesting MAG3-Cet with IdeS protease. (c) The HPLC result of the mixture from (b) but after reaction with protein A beads. The residual MAG3-Cet and most of the MAG3-Cet-Fc were removed by protein A beads.
Product Information
|
Product Name |
Product Number |
Specification |
|
IdeS Protease |
20412ES84/90 |
2000 U/5000 U |
Related Products Order
|
Product Name |
Product Number |
Specification |
|
Fast PNGase F (Glycerol-free) |
20406ES20/50 |
20 T/50 T |
|
PNGase F |
20407ES01/02 |
15000 U /75000 U |
|
Endo H |
20414ES92/97 |
10000 U /50000 U |
|
Endo S |
20413ES80/90 |
1000 U/5 x 1000 U |
Reference Literature
【1】Noninvasive Evaluation of EGFR Expression of Digestive Tumors Using 99mTc-MAG3-Cet-F(ab')2-Based SPECT/CT Imaging. Mol Imaging. 2022 Jun 24;2022:3748315. doi: 10.1155/2022/3748315.
【2】124I-Labeled Monoclonal Antibody and Fragment for the Noninvasive Evaluation of Tumor PD-L1 Expression In Vivo. Mol Pharm. 2022 Oct 3;19(10):3551-3562. doi: 10.1021/acs.molpharmaceut.2c00084.